10:21 AM EDT, 04/29/2024 (MT Newswires) -- Stoke Therapeutics ( STOK ) said Monday it has appointed Thomas Leggett as chief financial officer, succeeding Stephen Tulipano.

Leggett will join the company from Affinia Therapeutics where he served as CFO, the biotechnology company added.

Tulipano resigned as the company's finance chief, effective May 7, Stoke said.

Shares of the company were down 4% in recent trading.

Price: 11.91, Change: -0.50, Percent Change: -4.03